Douglas L Arnold

List of Publications by Year
in descending order

316 papers	29,784 citations	6254 80 h-index	5679 162 g-index
326 all docs	326 docs citations	326 times ranked	18292 citing authors

#	Article	IF	Citations
1	B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis. New England Journal of Medicine, 2008, 358, 676-688.	27.0	2,107
2	Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 1098-1107.	27.0	1,493
3	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	27.0	1,324
4	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	27.0	1,322
5	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1819-1828.	13.7	1,041
6	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1829-1839.	13.7	1,040
7	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
8	Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nature Medicine, 1996, 2, 323-325.	30.7	522
9	Rituximab in relapsing–remitting multiple sclerosis: A 72–week, open–label, phase I trial. Annals of Neurology, 2008, 63, 395-400.	5.3	484
10	Reversible decreases in N–acetylaspartate after acute brain injury. Magnetic Resonance in Medicine, 1995, 34, 721-727.	3.0	453
11	Evidence of Axonal Damage in the Early Stages of Multiple Sclerosis and Its Relevance to Disability. Archives of Neurology, 2001, 58, 65-70.	4.5	439
12	Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology, The, 2014, 13, 657-665.	10.2	339
13	Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Annals of Neurology, 1992, 31, 235-241.	5.3	311
14	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet, The, 2016, 388, 576-585.	13.7	296
15	Myoblast transfer in duchenne muscular dystrophy. Annals of Neurology, 1993, 34, 8-17.	5.3	291
16	Chemical pathology of acute demyelinating lesions and its correlation with disability. Annals of Neurology, 1995, 38, 901-909.	5.3	288
17	Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging. Medical Image Analysis, 2013, 17, 1-18.	11.6	280
18	Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease. Magnetic Resonance in Medicine, 1990, 14, 154-159.	3.0	275

#	Article	IF	Citations
19	Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurology, The, 2011, 10, 436-445.	10.2	267
20	Neuroimaging evidence of progressive neuronal loss and dysfunction in temporal lobe epilepsy. Annals of Neurology, 1999, 45, 568-576.	5.3	260
21	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2015, 373, 1418-1428.	27.0	245
22	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurology, 2020, 77, 1132.	9.0	245
23	Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Annals of Neurology, 2014, 75, 43-49.	5.3	240
24	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	10.2	238
25	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 1017-1027.	27.0	237
26	Alemtuzumab CARE-MS II 5-year follow-up. Neurology, 2017, 89, 1117-1126.	1.1	232
27	Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: A series of 100 patients. Annals of Neurology, 1997, 42, 737-746.	5.3	225
28	Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images. Annals of Neurology, 1994, 35, 211-216.	5.3	221
29	Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. New England Journal of Medicine, 2019, 380, 2406-2417.	27.0	219
30	Exploring uncertainty measures in deep networks for Multiple sclerosis lesion detection and segmentation. Medical Image Analysis, 2020, 59, 101557.	11.6	216
31	Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurology, 2020, 77, 82.	9.0	213
32	Robust Rician noise estimation for MR images. Medical Image Analysis, 2010, 14, 483-493.	11.6	200
33	Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Annals of Neurology, 1994, 36, 76-82.	5.3	192
34	Aerobic conditioning in patients with mitochondrial myopathies: Physiological, biochemical, and genetic effects. Annals of Neurology, 2001, 50, 133-141.	5.3	191
35	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020.	10.2	191
36	Alemtuzumab CARE-MS I 5-year follow-up. Neurology, 2017, 89, 1107-1116.	1.1	188

#	Article	IF	Citations
37	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033.	10.2	184
38	The Relationship Between Diffuse Axonal Damage and Fatigue in Multiple Sclerosis. Archives of Neurology, 2004, 61, 201.	4.5	181
39	Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. NeuroReport, 1998, 9, 1757-1761.	1.2	179
40	Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations. Canadian Journal of Neurological Sciences, 2013, 40, 307-323.	0.5	178
41	In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain, 1999, 122, 1933-1939.	7.6	176
42	Diffuse Axonal and Tissue Injury in Patients With Multiple Sclerosis With Low Cerebral Lesion Load and No Disability. Archives of Neurology, 2002, 59, 1565.	4.5	176
43	Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?. Acta Neuropathologica, 2012, 123, 627-638.	7.7	176
44	Multiple Sclerosis: Magnetization Transfer MR Imaging of White Matter before Lesion Appearance on T2-weighted Images. Radiology, 2000, 215, 824-830.	7.3	174
45	Axonal metabolic recovery in multiple sclerosis patients treated with interferon Î²-1b. Journal of Neurology, 2001, 248, 979-986.	3.6	171
46	Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Annals of Neurology, 2008, 63, 254-262.	5.3	169
47	Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial. Archives of Neurology, 2007, 64, 1407.	4.5	159
48	MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurology, The, 2011, 10, 1065-1073.	10.2	159
49	High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS). JAMA Neurology, 2015, 72, 159.	9.0	158
50	Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 35-46.	10.2	158
51	Texture analysis and morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy. Annals of Neurology, 2001, 49, 770-775.	5.3	156
52	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 373-381.	10.2	150
53	Proton Magnetic Resonance Spectroscopy for the Diagnosis and Management of Cerebral Disorders. Archives of Neurology, 1999, 56, 919.	4.5	149
54	Late-onset mitochondrial myopathy. Annals of Neurology, 1995, 37, 16-23.	5.3	139

#	ARTICLE	IF	CITATIONS
55	Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain, 2019, 142, 2787-2799.	7.6	136
56	A proton magnetic resonance spectroscopy study of focal epilepsy in humans. Neurology, 1990, 40, 985-985.	1.1	134
57	Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Annals of Neurology, 2013, 73, 341-354.	5.3	130
58	T2 Relaxometry Can Lateralize Mesial Temporal Lobe Epilepsy in Patients with Normal MRI. NeuroImage, 2000, 12, 739-746.	4.2	129
59	High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology, 2017, 88, 842-852.	1.1	128
60	Evaluating intensity normalization on MRIs of human brain with multiple sclerosis. Medical Image Analysis, 2011, 15, 267-282.	11.6	126
61	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple Sclerosis Journal, 2017, 23, 253-265.	3.0	126
62	How patients with multiple sclerosis acquire disability. Brain, 2022, 145, 3147-3161.	7.6	126
63	Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree. Annals of Neurology, 2000, 47, 179-185.	5.3	125
64	Automated detection of focal cortical dysplasia lesions using computational models of their MRI characteristics and texture analysis. NeuroImage, 2003, 19, 1748-1759.	4.2	125
65	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Multiple Sclerosis Journal, 2019, 25, 1915-1925.	3.0	122
66	2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Annals of Neurology, 2012, 72, 211-223.	5.3	117
67	Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nature Communications, 2021, 12, 2078.	12.8	112
68	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 845-856.	10.2	110
69	Magnetic Resonance Spectroscopy Guided Brain Tumor Resection: Differentiation Between Recurrent Glioma and Radiation Change in Two Diagnostically Difficult Cases. Canadian Journal of Neurological Sciences, 1998, 25, 13-22.	0.5	108
70	Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth. Neurology, 2014, 83, 2140-2146.	1.1	107
71	Magnetization transfer can predict clinical evolution in patients with multiple sclerosis. Journal of Neurology, 2002, 249, 662-668.	3.6	102
72	Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle and Nerve, 2000, 23, 1316-1334.	2.2	100

#	Article	IF	Citations
73	Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology, 2020, 95, 436-444.	1.1	100
74	Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, 378-388.	1.1	100
75	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 998-1009.	10.2	98
76	Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations. NeuroImage, 2015, 118, 126-132.	4.2	96
77	1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain, 2005, 128, 2483-2506.	7.6	94
78	Is Ictal Recording Mandatory in Temporal Lobe Epilepsy?. Archives of Neurology, 2000, 57, 497.	4.5	93
79	Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Multiple Sclerosis Journal, 2015, 21, 1025-1035.	3.0	91
80	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 729-738.	10.2	89
81	Interferon Beta Promotes Nerve Growth Factor Secretion Early in the Course of Multiple Sclerosis. Archives of Neurology, 2005, 62, 563.	4.5	87
82	Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. Journal of Neurology, 2017, 264, 304-315.	3.6	86
83	MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. The Lancet Child and Adolescent Health, 2018, 2, 191-204.	5.6	86
84	Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis. NeuroImage, 2010, 52, 1261-1267.	4.2	82
85	Five years of ocrelizumab in relapsing multiple sclerosis. Neurology, 2020, 95, e1854-e1867.	1.1	81
86	Cerebral dysgenesis and lactic acidemia: An MRI/MRS phenotype associated with pyruvate dehydrogenase deficiency. Pediatric Neurology, 1994, 11, 224-229.	2.1	80
87	Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. Journal of Neuroimmunology, 2006, 176, 198-215.	2.3	80
88	Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology, 2013, 80, 246-252.	1.1	79
89	In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using1H magnetic resonance spectroscopic imaging. Annals of Neurology, 1998, 44, 273-278.	5.3	78
90	Statistical power and prediction accuracy in multisite resting-state fMRI connectivity. NeuroImage, 2017, 149, 220-232.	4.2	78

#	Article	IF	Citations
91	Function and organization in dysgenic cortex. Journal of Neurosurgery, 1997, 87, 113-121.	1.6	76
92	Lesion distribution in children with clinically isolated syndromes. Annals of Neurology, 2008, 63, 401-405.	5.3	75
93	Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. NeuroImage: Clinical, 2014, 4, 10-17.	2.7	73
94	Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. Brain, 2019, 142, 617-632.	7.6	72
95	Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies. NeuroImage: Clinical, 2014, 6, 166-170.	2.7	71
96	MRI in the diagnosis and management of multiple sclerosis. Neurology, 2002, 58, S23-31.	1.1	71
97	Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. Journal of Neurology, 2014, 261, 1794-1802.	3.6	69
98	Proton magnetic resonance spectroscopic imaging for discrimination of absence and complex partial seizures. Annals of Neurology, 1997, 41, 74-81.	5.3	68
99	Using Proton Magnetic Resonance Spectroscopic Imaging to Predict in Vivo the Response of Recurrent Malignant Gliomas to Tamoxifen Chemotherapy. Neurosurgery, 2000, 46, 306-317.	1.1	68
100	Gradient distortions in MRI: Characterizing and correcting for their effects on SIENA-generated measures of brain volume change. NeuroImage, 2010, 49, 1601-1611.	4.2	68
101	Computational Models of MRI Characteristics of Focal Cortical Dysplasia Improve Lesion Detection. NeuroImage, 2002, 17, 1755-1760.	4.2	67
102	ADP Recovery After a Brief Ischemic Exercise in Normal and Diseased Human Muscle — a31P MRS Study. , 1996, 9, 165-172.		66
103	Effect of dimethyl fumarate on lymphocytes in RRMS. Neurology, 2019, 92, e1724-e1738.	1.1	66
104	Proton Magnetic Resonance Spectroscopic Imaging in Patients with Extratemporal Epilepsy. Epilepsia, 1998, 39, 267-273.	5.1	65
105	Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology, 2011, 69, 75-82.	5.3	65
106	Proton Magnetic Resonance Spectroscopic Imaging Can Predict Length of Survival in Patients with Supratentorial Gliomas. Neurosurgery, 2003, 53, 565-576.	1.1	64
107	Quantitative Determination of Regional Lesion Volume and Distribution in Children and Adults with Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2014, 9, e85741.	2.5	64
108	Towards a better understanding of *pseudoatrophy* in the brain of multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 675-676.	3.0	64

#	Article	IF	Citations
109	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	10.2	64
110	Changes in cognitive performance over a 1-year period in children and adolescents with multiple sclerosis.. Neuropsychology, 2013, 27, 210-219.	1.3	63
111	Trimmed-Likelihood Estimation for Focal Lesions and Tissue Segmentation in Multisequence MRI for Multiple Sclerosis. IEEE Transactions on Medical Imaging, 2011, 30, 1455-1467.	8.9	62
112	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology, 2013, 260, 2297-2305.	3.6	62
113	Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis. Neurology, 2015, 85, 1663-1669.	1.1	62
114	Morphometric MRI Analysis of the Parahippocampal Region in Temporal Lobe Epilepsy. Annals of the New York Academy of Sciences, 2000, 911, 495-500.	3.8	61
115	Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter. NeuroImage, 2006, 29, 637-642.	4.2	59
116	Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology, 2014, 83, 2219-2226.	1.1	58
117	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis Journal, 2019, 25, 1605-1617.	3.0	57
118	Temporally Consistent Probabilistic Detection of New Multiple Sclerosis Lesions in Brain MRI. IEEE Transactions on Medical Imaging, 2013, 32, 1490-1503.	8.9	56
119	Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. NeuroImage, 2013, 66, 103-109.	4.2	56
120	Rotation-invariant multi-contrast non-local means for MS lesion segmentation. NeuroImage: Clinical, 2015, 8, 376-389.	2.7	56
121	The role of edema and demyelination in chronic T1 black holes: A quantitative magnetization transfer study. Journal of Magnetic Resonance Imaging, 2005, 21, 103-110.	3.4	55
122	Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. Journal of Neurology, 2003, 250, 924-931.	3.6	54
123	Automated quality control of brain MR images. Journal of Magnetic Resonance Imaging, 2008, 28, 308-319.	3.4	54
124	Mitochondrial Disease. Chest, 1995, 108, 182-189.	0.8	53
125	Imaging outcome measures of neuroprotection and repair in MS. Neurology, 2019, 92, 519-533.	1.1	53
126	Imaging of axonal damage in vivo in Rasmussen's syndrome. Brain, 1995, 118, 753-758.	7.6	52

#	Article	IF	Citations
127	Entorhinal Cortex MRI Assessment in Temporal, Extratemporal, and Idiopathic Generalized Epilepsy. Epilepsia, 2003, 44, 1070-1074.	5.1	52
128	Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2016, 15, 1148-1159.	10.2	52
129	White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. Brain, 2017, 140, 1300-1315.	7.6	52
130	Measuring Demyelination and Remyelination in Acute Multiple Sclerosis Lesion Voxels. Archives of Neurology, 2009, 66, 375-81.	4.5	51
131	Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study. Multiple Sclerosis Journal, 2014, 20, 243-252.	3.0	51
132	Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Multiple Sclerosis Journal, 2016, 22, 385-388.	3.0	50
133	High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e598.	6.0	50
134	Magnetic resonance spectroscopy in niemann-pick disease type C: Correlation with diagnosis and clinical response to cholestyramine and lovastatin. Pediatric Neurology, 1994, 10, 228-232.	2.1	49
135	Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. Journal of Neurology, 2006, 253, 1060-1063.	3.6	49
136	Impairment of muscle mitochondrial oxidative metabolism in McArdle's disease. , 1996, 19, 764-769.		48
137	Efficacy of delayed‐release dimethyl fumarate in relapsing‐remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology, 2015, 2, 103-118.	3.7	48
138	Application of calibrated fMRI in Alzheimer's disease. NeuroImage: Clinical, 2017, 15, 348-358.	2.7	48
139	ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 686-695.	3.0	47
140	Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642091500.	3.5	47
141	Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution. Current Opinion in Neurology, 2001, 14, 279-287.	3.6	46
142	Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies. Biology of Blood and Marrow Transplantation, 2010, 16, 1076-1083.	2.0	46
143	Imaging of repeated episodes of demyelination and remyelination in multiple sclerosis. NeuroImage: Clinical, 2014, 6, 20-25.	2.7	46
144	Characterization of astrocytomas, meningiomas, and pituitary adenomas by phosphorus magnetic resonance spectroscopy. Journal of Neurosurgery, 1991, 74, 447-453.	1.6	45

#	Article	IF	Citations
145	Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurements. NeuroImage, 2019, 184, 555-565.	4.2	45
146	Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: Consensus report of the white matter study group. Journal of Magnetic Resonance Imaging, 2005, 21, 669-675.	3.4	43
147	Monophasic demyelination reduces brain growth in children. Neurology, 2017, 88, 1744-1750.	1.1	43
148	MRI in the evaluation of pediatric multiple sclerosis. Neurology, 2016, 87, S88-96.	1.1	42
149	A surface€in gradient of thalamic damage evolves in pediatric multiple sclerosis. Annals of Neurology, 2019, 85, 340-351.	5.3	42
150	Surface-based analysis reveals regions of reduced cortical magnetization transfer ratio in patients with multiple sclerosis: A proposed method for imaging subpial demyelination. Human Brain Mapping, 2014, 35, 3402-3413.	3.6	41
151	Diroximel fumarate (DRF) in patients with relapsing€"remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis Journal, 2020, 26, 1729-1739.	3.0	41
152	Proton magnetic resonance spectroscopic images and MRI volumetric studies for lateralization of temporal lobe epilepsy. Magnetic Resonance Imaging, 1995, 13, 1187-1191.	1.8	40
153	Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurology, 2014, 14, 240.	1.8	40
154	Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. American Journal of Neuroradiology, 2003, 24, 476-80.	2.4	40
155	Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI Using Conditional Random Fields. IEEE Transactions on Medical Imaging, 2012, 31, 1181-1194.	8.9	38
156	Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 599-607.	3.0	38
157	Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. Journal of Neurology, 2014, 261, 2429-2437.	3.6	37
158	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262.	3.0	37
159	1H NMR characterization of normal human cerebrospinal fluid and the detection of methylmalonic acid in a vitamin B12 deficient patient. NMR in Biomedicine, 1991, 4, 192-200.	2.8	36
160	Evidence for mitochondrial dysfunction in patients with alternating hemiplegia of childhood. Annals of Neurology, 1993, 33, 604-607.	5.3	36
161	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 1001-1011.	10.2	36
162	N-acetylaspartate: Usefulness as an indicator of viable neuronal tissue. Annals of Neurology, 2001, 50, 823-823.	5.3	35

#	Article	IF	Citations
163	Elevated serum inflammatory markers in post-poliomyelitis syndrome. Journal of the Neurological Sciences, 2008, 271, 80-86.	0.6	34
164	Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI. American Journal of Neuroradiology, 2019, 40, 1162-1169.	2.4	34
165	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Annals of Clinical and Translational Neurology, 2021, 8, 2252-2269.	3.7	34
166	Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 420-431.	3.0	33
167	Silent New Brain MRI Lesions in Children with MOGâ€Antibody Associated Disease. Annals of Neurology, 2021, 89, 408-413.	5.3	33
168	MR SPECTROSCOPY AND MR IMAGING IN METABOLIC MYOPATHIES. Neurologic Clinics, 2000, 18, 35-52.	1.8	32
169	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	1.0	32
170	The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. Multiple Sclerosis Journal, 2019, 25, 515-522.	3.0	32
171	A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of avonex in patients with multiple sclerosis. Clinical Therapeutics, 2004, 26, 511-521.	2.5	31
172	Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. Neurology, 2013, 81, 1215-1221.	1.1	31
173	White matter plasticity and maturation in human cognition. Glia, 2019, 67, 2020-2037.	4.9	31
174	Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. Journal of Neurology, 2013, 260, 1901-1906.	3.6	30
175	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098213.	3.5	30
176	Magnetic Resonance Spectroscopy in Epilepsy: Clinical Issues. Epilepsia, 2002, 43, 32-39.	5.1	28
177	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon Î²-1a in MS. Neurology, 2016, 87, 1464-1472.	1.1	28
178	Fatigue in Postâ€poliomyelitis Syndrome: Association With Diseaseâ€Related, Behavioral, and Psychosocial Factors. PM and R, 2009, 1, 442-449.	1.6	27
179	Reproducibility of quantitative magnetizationâ€transfer imaging parameters from repeated measurements. Magnetic Resonance in Medicine, 2010, 64, 391-400.	3.0	27
180	Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes. JAMA Network Open, 2021, 4, e2128871.	5.9	27

#	Article	IF	Citations
181	Intracellular phosphates in inclusion body myositis?A 31P magnetic resonance spectroscopy study. , 1998, 21, 1523-1525.		26
182	Magnetization transfer ratio recovery in new lesions decreases during adolescence in pediatric-onset multiple sclerosis patients. NeuroImage: Clinical, 2014, 6, 237-242.	2.7	26
183	Probabilistic Multiple Sclerosis Lesion Classification Based on Modeling Regional Intensity Variability and Local Neighborhood Information. IEEE Transactions on Biomedical Engineering, 2015, 62, 1281-1292.	4.2	26
184	Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1605-1616.	3.0	26
185	Incidence and prevalence of MS in children. Neurology, 2018, 91, e1579-e1590.	1.1	26
186	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG*MS* study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 483-492.	1.9	26
187	Long-term safety and efficacy of dimethyl fumarate for up to 13â€‰years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Multiple Sclerosis Journal, 2022, 28, 801-816.	3.0	26
188	Early Metabolic Changes Following Chemotherapy of Human Gliomas In Vivo Demonstrated by Phosphorus Magnetic Resonance Spectroscopy. Investigative Radiology, 1989, 24, 958-961.	6.2	25
189	Lateralization of Temporal Lobe Epilepsy (TLE) and Discrimination of TLE from Extra-TLE Using Pattern Analysis of Magnetic Resonance Spectroscopic and Volumetric Data. Epilepsia, 2000, 41, 832-842.	5.1	25
190	Adaptive multi-level conditional random fields for detection and segmentation of small enhanced pathology in medical images. Medical Image Analysis, 2016, 27, 17-30.	11.6	25
191	A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731774309.	1.0	25
192	Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation. Multiple Sclerosis Journal, 2021, 27, 2062-2076.	3.0	25
193	Memory Performance and Normalized Regional Brain Volumes in Patients with Pediatric-Onset Multiple Sclerosis. Journal of the International Neuropsychological Society, 2012, 18, 471-480.	1.8	24
194	Large, Nonplateauing Relationship Between Clinical Disability and Cerebral White Matter Lesion Load in Patients With Multiple Sclerosis. Archives of Neurology, 2012, 69, 89.	4.5	24
195	Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial. BMC Neurology, 2017, 17, 29.	1.8	24
196	The Lesions of Multiple Sclerosis. New England Journal of Medicine, 2002, 346, 199-200.	27.0	23
197	Intracortical inhibition abnormality during the remission phase of multiple sclerosis is related to upper limb dexterity and lesions. Clinical Neurophysiology, 2016, 127, 1503-1511.	1.5	23
198	Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. Multiple Sclerosis Journal, 2021, 27, 1497-1505.	3.0	23

#	Article	IF	Citations
199	1H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 72-79.	0.6	22
200	Phase IV study of retention on fingolimod <i>versus</i> injectable multiple sclerosis therapies: a randomized clinical trial. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877433.	3.5	22
201	Glutaric acidemia type II: Neuroimaging and spectroscopy evidence for developmental encephalomyopathy. Pediatric Neurology, 1995, 12, 350-353.	2.1	21
202	Relation of Interictal Spike Frequency to 1H-MRSI-Measured NAA/Cr. Epilepsia, 1999, 40, 1821-1827.	5.1	21
203	Proton Magnetic Resonance Spectroscopic Imaging Studies in Patients with Newly Diagnosed Partial Epilepsy. Epilepsia, 2000, 41, 825-831.	5.1	21
204	Axonal Damage in Multiple Sclerosis Patients with High versus Low Expanded Disability Status Scale Score. Canadian Journal of Neurological Sciences, 2004, 31, 225-228.	0.5	21
205	Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. Journal of Neuro-Oncology, 2008, 90, 63-76.	2.9	21
206	Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis. Current Opinion in Neurology, 2008, 21, 272-277.	3.6	21
207	Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease. Multiple Sclerosis Journal, 2016, 22, 1266-1278.	3.0	21
208	Multiple Sclerosis Lesion Segmentation Using an Automatic Multimodal Graph Cuts. Lecture Notes in Computer Science, 2009, 12, 584-591.	1.3	21
209	Altered resting-state functional connectivity in cognitively preserved pediatric-onset MS patients and relationship to structural damage and cognitive performance. Multiple Sclerosis Journal, 2016, 22, 792-800.	3.0	20
210	Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 767-775.	3.7	20
211	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Multiple Sclerosis and Related Disorders, 2021, 48, 102673.	2.0	20
212	Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 995-1006.	1.9	20
213	Evidence for neuroprotection and remyelination using imaging techniques. Neurology, 2007, 68, S83-S90.	1.1	19
214	Masquerades of Acquired Demyelination in Children. Journal of Child Neurology, 2013, 28, 184-197.	1.4	19
215	Non-Local Means Inpainting of MS Lesions in Longitudinal Image Processing. Frontiers in Neuroscience, 2015, 9, 456.	2.8	19
216	Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions. American Journal of Neuroradiology, 2020, 41, 1584-1591.	2.4	19

#	Article	IF	Citations
217	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders, 2021, 51, 102844.	2.0	19
218	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5â€°years. Multiple Sclerosis Journal, 2022, 28, 1591-1605.	3.0	19
219	Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology, 2022, 13, 852563.	4.8	18
220	Association of cerebral dysgenesis and lactic acidemia with X-linked PDH E1Î± subunit mutations in females. Pediatric Neurology, 1995, 13, 327-332.	2.1	17
221	Temporal Hierarchical Adaptive Texture CRF for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI. IEEE Transactions on Medical Imaging, 2015, 34, 1227-1241.	8.9	17
222	IMaGe: Iterative Multilevel Probabilistic Graphical Model for Detection and Segmentation of Multiple Sclerosis Lesions in Brain MRI. Lecture Notes in Computer Science, 2015, 24, 514-526.	1.3	17
223	Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies. NeuroImage, 2020, 208, 116442.	4.2	17
224	Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways. Journal of Neurology, 2005, 252, v25-v29.	3.6	16
225	Quantitative Measurement of tissue damage and recovery within new T2w lesions in pediatric- and adult-onset multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 718-725.	3.0	16
226	MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon Î²-1b. Neurology, 2016, 87, 905-911.	1.1	16
227	Noâ€reference quality measure in brain MRI images using binary operations, texture and set analysis. IET Image Processing, 2017, 11, 672-684.	2.5	16
228	MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis. Neurology, 2017, 89, 714-721.	1.1	16
229	Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879114.	3.5	16
230	Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. BMJ Open, 2020, 10, e038861.	1.9	16
231	Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the PhaseÂ3 EVOLVE-MS-1 Study. Advances in Therapy, 2022, 39, 1810-1831.	2.9	16
232	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal, 2022, 28, 1526-1540.	3.0	16
233	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€°years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal, 2022, 28, 1944-1962.	3.0	16
234	High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study. PLoS ONE, 2019, 14, e0218215.	2.5	15

#	Article	IF	Citations
235	Improved Precision in the Measurement of Longitudinal Global and Regional Volumetric Changes via a Novel MRI Gradient Distortion Characterization and Correction Technique. Lecture Notes in Computer Science, 2010, , 324-333.	1.3	15
236	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. Neurology, 2022, 98, .	1.1	15
237	Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Biochemical Society Transactions, 1985, 13, 654-654.	3.4	14
238	Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1055-1066.	3.0	14
239	Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters. BioMedical Engineering OnLine, 2018, 17, 76.	2.7	14
240	Familial myopathy with conspicuous depletion of mitochondria in muscle fibers: a morphologically distinct disease. Neuromuscular Disorders, 1995, 5, 139-144.	0.6	13
241	Neuronal dysfunction in children with newly diagnosed temporal lobe epilepsy. Pediatric Neurology, 2000, 22, 281-286.	2.1	13
242	Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise. Brain Communications, 2021, 3, fcab176.	3.3	13
243	CNN Detection of New and Enlarging Multiple Sclerosis Lesions from Longitudinal Mri Using Subtraction Images. , 2020, , .		12
244	Propagating Uncertainty Across Cascaded Medical Imaging Tasks for Improved Deep Learning Inference. IEEE Transactions on Medical Imaging, 2022, 41, 360-373.	8.9	12
245	Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. Multiple Sclerosis Journal, 2022, 28, 1697-1709.	3.0	12
246	Chronic lesion activity and disability progression in secondary progressive multiple sclerosis. BMJ Neurology Open, 2022, 4, e000240.	1.6	12
247	Normalization of White Matter Intensity on T1â€Weighted Images of Patients with Acquired Central Nervous System Demyelination. Journal of Neuroimaging, 2015, 25, 184-190.	2.0	11
248	Subgroup and sensitivity analyses of annualized relapse rate over 2Âyears in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis. Journal of Neurology, 2016, 263, 1778-1787.	3.6	11
249	Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI. Multiple Sclerosis Journal, 2019, 25, 980-986.	3.0	11
250	Brain volume loss in individuals over time: Source of variance and limits of detectability. NeuroImage, 2020, 214, 116737.	4.2	11
251	Automated separation of diffusely abnormal white matter from focal white matter lesions on MRI in multiple sclerosis. NeuroImage, 2020, 213, 116690.	4.2	11
252	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 48.	9.0	11

#	Article	IF	Citations
253	Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731663411.	1.0	10
254	Increased mental health care use by mothers of children with multiple sclerosis. Neurology, 2020, 94, e1040-e1050.	1.1	10
255	Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Multiple Sclerosis Journal, 2022, 28, 1927-1936.	3.0	10
256	Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis. Clinical Neuropharmacology, 2015, 38, 127-131.	0.7	9
257	Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1948-1959.	3.0	9
258	Slowly expanding lesions are a marker of progressive MS â€" No. Multiple Sclerosis Journal, 2021, 27, 1681-1683.	3.0	9
259	Defining Multiple Sclerosis Treatment Response With Magnetic Resonance Imaging. Archives of Neurology, 2009, 66, 19.	4.5	8
260	Adaptive Voxel, Texture and Temporal Conditional Random Fields for Detection of Gad-Enhancing Multiple Sclerosis Lesions in Brain MRI. Lecture Notes in Computer Science, 2013, 16, 543-550.	1.3	8
261	Detection of Gad-Enhancing Lesions in Multiple Sclerosis Using Conditional Random Fields. Lecture Notes in Computer Science, 2010, 13, 41-48.	1.3	8
262	Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurology, The, 2005, 4, 74-75.	10.2	7
263	Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731667664.	1.0	7
264	Cognitive and Behavioral Functioning in Childhood Acquired Demyelinating Syndromes. Journal of the International Neuropsychological Society, 2016, 22, 1050-1060.	1.8	7
265	Delineation of cortical pathology in multiple sclerosis using multi-surface magnetization transfer ratio imaging. NeuroImage: Clinical, 2016, 12, 858-868.	2.7	7
266	Bayesian framework inspired no-reference region-of-interest quality measure for brain MRI images. Journal of Medical Imaging, 2017, 4, 025504.	1.5	7
267	Predicting Future Disease Activity and Treatment Responders for Multiple Sclerosis Patients Using a Bag-of-Lesions Brain Representation. Lecture Notes in Computer Science, 2017, , 186-194.	1.3	7
268	Image Quality Evaluation in Clinical Research: A Case Study on Brain and Cardiac MRI Images in Multi-Center Clinical Trials. IEEE Journal of Translational Engineering in Health and Medicine, 2018, 6, 1-15.	3.7	7
269	Factors associated with health care utilization in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 38, 101511.	2.0	7
270	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104.	3.6	7

#	Article	IF	Citations
271	Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731558977.	1.0	6
272	Improving the SIENA performance using BEaST brain extraction. PLoS ONE, 2018, 13, e0196945.	2.5	6
273	Peginterferon Î²-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsingâ€"remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879508.	3.5	6
274	Texture analysis and morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extraâ€‑temporal partial epilepsy. Annals of Neurology, 2001, 49, 770-775.	5.3	6
275	Lesion Detection, Segmentation and Prediction in Multiple Sclerosis Clinical Trials. Lecture Notes in Computer Science, 2018, , 15-28.	1.3	6
276	The clique potential of Markov random field in a random experiment for estimation of noise levels in 2D brain MRI. International Journal of Imaging Systems and Technology, 2013, 23, 304-313.	4.1	5
277	Brain Volume and Fatigue in Patients With Postpoliomyelitis Syndrome. PM and R, 2014, 6, 215-220.	1.6	5
278	Optimal selection of regularization parameter in total variation method for reducing noise in magnetic resonance images of the brain. Biomedical Engineering Letters, 2014, 4, 80-92.	4.1	5
279	The spatial statistics of structural magnetic resonance images: application to post-acquisition quality assessment of brain MRI images. Imaging Science Journal, 2017, 65, 468-483.	0.5	5
280	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	3.0	5
281	Propagating Uncertainty Across Cascaded Medical Imaging Tasks for Improved Deep Learning Inference. Lecture Notes in Computer Science, 2019, , 23-32.	1.3	5
282	A Generative Model for Automatic Detection of Resolving Multiple Sclerosis Lesions. Lecture Notes in Computer Science, 2014, , 118-129.	1.3	5
283	Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation. Brain, 2022, 145, 2008-2017.	7.6	5
284	The place of MRI in monitoring the individual MS patient. Journal of the Neurological Sciences, 2007, 259, 123-127.	0.6	4
285	The Metabolic Epicenter of Supratentorial Gliomas: A ^{1}H-MRSI Study. Canadian Journal of Neurological Sciences, 2009, 36, 696-706.	0.5	4
286	Imaging of Demyelination and Remyelination in Multiple Sclerosis. , 2013, , 233-253.		4
287	Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e499.	6.0	4
288	Local Indicators of Spatial Autocorrelation (LISA): Application to Blind Noise-Based Perceptual Quality Metric Index for Magnetic Resonance Images. Journal of Imaging, 2019, 5, 20.	3.0	4

#	Article	IF	Citations
289	CNN Prediction of Future Disease Activity for Multiple Sclerosis Patients from Baseline MRI and Lesion Labels. Lecture Notes in Computer Science, 2019, , 57-69.	1.3	4
290	Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098794.	3.5	4
291	Hierarchical Conditional Random Fields for Detection of Gad-Enhancing Lesions in Multiple Sclerosis. Lecture Notes in Computer Science, 2012, 15, 379-386.	1.3	4
292	Assessing the differential sensitivities of wave-CAIPI ViSTa myelin water fraction and magnetization transfer saturation for efficiently quantifying tissue damage in MS. Multiple Sclerosis and Related Disorders, 2021, 56, 103309.	2.0	4
293	Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103149.	2.0	3
294	Letters to the editor. Muscle and Nerve, 1987, 10, 183-184.	2.2	2
295	Chapter 10 Magnetic Resonance Imaging and Spectroscopy: Insights into the Pathology and Pathophysiology of Multiple Sclerosis. Blue Books of Practical Neurology, 2003, 27, 139-167.	0.1	2
296	Path Sampling to Compute Integrated Likelihoods: An Adaptive Approach. Journal of Computational and Graphical Statistics, 2009, 18, 415-437.	1.7	2
297	Longitudinal change in Paced Auditory Serial Addition Test (PASAT) performance following immunoablative therapy and haematopoietic stem cell transplant in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	2
298	Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study. Journal of Neurology, 2017, 264, 1728-1734.	3.6	2
299	Standardized quality metric system for structural brain magnetic resonance images in multi-center neuroimaging study. BMC Medical Imaging, 2018, 18, 31.	2.7	2
300	Saliency Based Deep Neural Network for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI. Lecture Notes in Computer Science, 2020, , 108-118.	1.3	2
301	Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN. Multiple Sclerosis and Related Disorders, 2022, 57, 103367.	2.0	2
302	Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies. Frontiers in Neurology, 2022, 13, 809273.	2.4	2
303	Progressive retinal changes in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 61, 103761.	2.0	2
304	The search for the missing links in multiple sclerosis. Current Neurology and Neuroscience Reports, 2007, 7, 93-94.	4.2	1
305	Axonal pathology in patients with multiple sclerosis. , 2011, , 150-164.		1
306	056…Efficacy and safety of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A18.2-A19.	1.9	1

#	Article	IF	Citations
307	Differential Diagnosis of Human Intracranial Tumors in Vivo Using 1H Mr Spectroscopic Imaging and Feature Space for Spectral Pattern Recognition. , 1994, , 299-313.		1
308	Is It Possible to Differentiate the Impact of Pediatric Monophasic Demyelinating Disorders and Multiple Sclerosis After a First Episode of Demyelination?. Lecture Notes in Computer Science, 2015, , 38-48.	1.3	1
309	Windows on the working brain: magnetic resonance spectroscopy. , 2002, , 146-159.		0
310	Chapter 54 MRS for imaging neuronal dysfunction in epilepsy. Supplements To Clinical Neurophysiology, 2002, , 359-364.	2.1	0
311	Reply. Annals of Neurology, 2014, 75, 463-464.	5.3	0
312	Four€neighborhood clique kernel: A general framework for Bayesian and variational techniques of noise reduction in magnetic resonance images of the brain. International Journal of Imaging Systems and Technology, 2014, 24, 224-238.	4.1	0
313	Cohort Bias Adaptation in Aggregated Datasets for Lesion Segmentation. Lecture Notes in Computer Science, 2021, , 101-111.	1.3	0
314	Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study. Child Neuropsychology, 2021, , 1-22.	1.3	0
315	Patterns of white and gray structural abnormality associated with paediatric demyelinating disorders. NeuroImage: Clinical, 2022, 34, 103001.	2.7	0
316	Evobrutinib reduces volume of slowly expanding lesions. , 0, , .		0